The Library
Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial
Tools
Tools
Tools
Davies, Melanie J., Russell-Jones, David, Barber, Thomas M., Lavalle-Gonzalez, Fernando J., Galstyan, Gagik R., Zhu, Dhalong, Baxter, Mike, Dessapt-Baradez, Cecile and McCrimmon, Rory J. (2019) Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial. Diabetes, Obesity and Metabolism, 21 (8). pp. 1967-1972. doi:10.1111/dom.13791 ISSN 1462-8902.
|
PDF
WRAP-iGlarLixi-glycaemic-patient-LixiLan-O-trial-Barber-2019.pdf - Accepted Version - Requires a PDF viewer. Download (1474Kb) | Preview |
Official URL: https://doi.org/10.1111/dom.13791
Abstract
In this post hoc analysis of the randomized controlled LixiLan‐O trial in insulin‐naive type 2 diabetes mellitus (T2DM) patients not controlled on metformin with or without a second oral antihyperglycaemic drug (OAD), the efficacy and safety of the fixed‐ratio combination, iGlarLixi (insulin glargine 100 U [iGlar] and lixisenatide [Lixi]), compared to its individual components was assessed in two patient subgroups: (1) a baseline HbA1c ≥9% (n = 134); (2) inadequate control (HbA1c ≥7.0% and ≤9.0%) despite administration of two OADs at screening (n = 725).
Treatment with iGlarLixi resulted in a significantly greater reduction in least squares mean HbA1c compared with iGlar or Lixi alone in both subgroups (HbA1c ≥9% group: 2.9%, 2.5%, 1.7%; two OADs group: 1.5%, 1.2%, 0.7%, respectively). Target HbA1c <7% was achieved in >70% of patients on iGlarLixi in both subgroups, while mitigating the weight gain observed with iGlar alone. Rates of hypoglycaemic events were low overall.
These results suggest that iGlarLixi achieves superior glycaemic control compared with iGlar or Lixi alone in T2DM patients with HbA1c ≥9% or those inadequately controlled on two OADs.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) |
||||||||
| Journal or Publication Title: | Diabetes, Obesity and Metabolism | ||||||||
| Publisher: | Blackwell | ||||||||
| ISSN: | 1462-8902 | ||||||||
| Official Date: | August 2019 | ||||||||
| Dates: |
|
||||||||
| Volume: | 21 | ||||||||
| Number: | 8 | ||||||||
| Page Range: | pp. 1967-1972 | ||||||||
| DOI: | 10.1111/dom.13791 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Reuse Statement (publisher, data, author rights): | "This is the peer reviewed version of the following article:Davies, M. J., Russell‐Jones, D. , Barber, T. M., Lavalle‐González, F. J., Galstyan, G. R., Zhu, D. , Baxter, M. , Dessapt‐Baradez, C. and McCrimmon, R. J. (2019), Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial. Diabetes Obes Metab. Accepted Author Manuscript. doi:10.1111/dom.13791, which has been published in final form at https://doi.org/10.1111/dom.13791. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions." | ||||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||||
| Date of first compliant deposit: | 30 May 2019 | ||||||||
| Date of first compliant Open Access: | 24 May 2020 |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
